| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 06/02/2009 | US7541153 Screening a substance interfering in the association of Dedicator of cytokinesis 2 (DOCK2) and engulfment and cell motility 1(ELMO1); drug screening; allergy, autoimmune diseases, GvH, graft rejection |
| 06/02/2009 | US7541139 Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins |
| 06/02/2009 | US7541033 Humanized anti-IL-1β antibodies |
| 06/02/2009 | US7541031 Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα |
| 06/02/2009 | US7541029 Anti-rhesus D monoclonal antibodies |
| 06/02/2009 | CA2425395C Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 06/02/2009 | CA2349633C A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 06/02/2009 | CA2344290C Quinazoline derivatives |
| 06/02/2009 | CA2321664C Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 06/02/2009 | CA2258539C Ring-fused dihydropyranes, process for the preparation and use thereof |
| 06/02/2009 | CA2158475C Composition and method for reducing toxicity of biologically-active factors |
| 06/02/2009 | CA2068863C Particle-mediated transformation of animal tissue cells |
| 05/28/2009 | WO2009067699A2 Methods for providing a system of care for an oxazaphosphorine drug regimen |
| 05/28/2009 | WO2009067630A1 2-amino purine derivatives and their use as anti-herpetic agents |
| 05/28/2009 | WO2009066775A1 Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same |
| 05/28/2009 | WO2009066681A1 Lactic acid bacterium-containing preparation |
| 05/28/2009 | WO2009066537A1 Immunoregulatory function inducer and food composition |
| 05/28/2009 | WO2009066462A1 Method for induction of cytotoxic t-cell, cytotoxic t-cell inducer, and pharmaceutical composition and vaccine each comprising the inducer |
| 05/28/2009 | WO2009065946A2 Pharmaceutical kit consisting of an oil-in-water emulsion and a solid composition |
| 05/28/2009 | WO2009065561A2 System for delivery into a xcr1 positive cell and uses thereof |
| 05/28/2009 | WO2009065296A1 Gene engineering immunorepressive polypeptides and their preparing methods and uses |
| 05/28/2009 | WO2009046880A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009046877A3 Use of a histrelin and leuprolide as therapeutic agents |
| 05/28/2009 | WO2009046858A3 Therapeutic uses of kisspeptin 13 and compositions thereof |
| 05/28/2009 | WO2009046822A3 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009045313A3 Oxypiperidine derivatives as histamine receptor antagonists |
| 05/28/2009 | WO2009043527A3 Therapeutic use of human growth hormone 1-43 |
| 05/28/2009 | WO2009043521A3 Use of urocortin iii and urocortin i as therapeutic agents |
| 05/28/2009 | WO2009043506A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009043456A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009043155A3 Distinct hiv-1 gag and env epitopes of hla alleles associated with differential susceptibility to hiv-1 infection |
| 05/28/2009 | WO2009040051A3 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009040023A3 Use of galnon as a therapeutic agent |
| 05/28/2009 | WO2009040005A3 Use of the peptide rfmwmr as a therapeutic agent |
| 05/28/2009 | WO2009039985A3 Therapeutic uses of urocortin ii |
| 05/28/2009 | WO2009039984A3 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 05/28/2009 | WO2009039983A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009039978A3 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 05/28/2009 | WO2009033747A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009033660A3 Use of octreotide as a therapeutic agent |
| 05/28/2009 | WO2008130382A3 Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
| 05/28/2009 | WO2008098789A3 Dual acting prodrugs |
| 05/28/2009 | US20090137845 Novel 4-Dedimethylaminotetracycline derivatives |
| 05/28/2009 | US20090137660 Cytokine Modulators Using Cyclic Glycerides of Essential Polyunsaturated Fatty Acids |
| 05/28/2009 | US20090137647 Modified Macrophage Migration Inhibitory Factor Inhibitors |
| 05/28/2009 | US20090137606 Chewable formulations |
| 05/28/2009 | US20090137604 corticotropin releasing factor receptor antagonists such as 8-(N-butyl-N-(2-butynyl)amino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, used for the treatment of nervous system, psychological, eating, sleep, and gastrointestinal disorders |
| 05/28/2009 | US20090137588 Heteroaryl compounds and uses thereof |
| 05/28/2009 | US20090137581 Heterocyclic compounds and their uses |
| 05/28/2009 | US20090137530 Amine Compound and Use Thereof for Medical Purposes |
| 05/28/2009 | US20090137527 Compositions and methods for modulating immune function |
| 05/28/2009 | US20090137513 RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 05/28/2009 | US20090137512 nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases |
| 05/28/2009 | US20090137511 RNA INTERFERENCE MEDIATED INHIBITION OF PLACENTAL GROWTH FACTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137509 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137508 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 05/28/2009 | US20090137494 Tumor-activated prodrug compounds and treatment |
| 05/28/2009 | US20090137476 Apo-2 ligand variants and uses thereof |
| 05/28/2009 | US20090137464 Therapeutic fibrin-derived peptides and uses thereof |
| 05/28/2009 | US20090137453 Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof |
| 05/28/2009 | US20090137036 Tweak receptor |
| 05/28/2009 | US20090137035 Tweak receptor |
| 05/28/2009 | US20090136602 Natural immunostimulant compositions, methods for obtaining the same and pharmaceutical formulations thereof |
| 05/28/2009 | US20090136548 Multiple antigenic peptides immunogenic against streptococcus pneumonia |
| 05/28/2009 | US20090136536 Recombinant Subunit Vaccine |
| 05/28/2009 | US20090136534 A recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which Mtb antigens and Mtb resuscitation or reactivation antigens are overexpressed, and a portion of the DosR regulon is up-regulated; prevent establishment of latent TB or reactivated disease in adolescents/adults |
| 05/28/2009 | US20090136525 Immunoglobulins Comprising Predominantly a Glcnacman3Glcnac2 Glycoform |
| 05/28/2009 | US20090136516 Cd-20 specific antibodies and methods of employing same |
| 05/28/2009 | US20090136493 Modified fusion molecules for treatment of allergic disease |
| 05/28/2009 | CA2706536A1 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
| 05/28/2009 | CA2706391A1 Spiropiperidines for use as tryptase inhibitors |
| 05/28/2009 | CA2705588A1 System for delivery into a xcr1 positive cell and uses thereof |
| 05/27/2009 | EP2062977A1 Fucosyltransferase-gen |
| 05/27/2009 | EP2062970A1 Compositions for treating an intestinal inflammatory condition |
| 05/27/2009 | EP2062968A1 Bacterial strain having anti-allergic activity, and beverage, food and anti-allergic agent comprising cell of the bacterial strain |
| 05/27/2009 | EP2062914A2 Somatostatin-dopamine chimeric analogs |
| 05/27/2009 | EP2062884A1 Novel phenylacetic acid derivative |
| 05/27/2009 | EP2062879A1 Heterocyclic inhibitors of p38 |
| 05/27/2009 | EP2062595A1 Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists |
| 05/27/2009 | EP2062592A1 System for delivery into a XCR1 positive cell and uses thereof |
| 05/27/2009 | EP2062586A2 Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors |
| 05/27/2009 | EP2062583A2 Therapeutic applications of pro-apoptotic benzodiazepines |
| 05/27/2009 | EP2061886A1 Small cationic antimicrobial peptides |
| 05/27/2009 | EP2061812A1 Method for producing antibodies |
| 05/27/2009 | EP2061811A2 Variable region sequences of il-31 monoclonal antibodies and methods of use |
| 05/27/2009 | EP2061759A1 Cyclic modulators of chemokine receptor activity |
| 05/27/2009 | EP2061446A2 Use of cdk inhibitors for the treatment of granulocyte mediated disorders |
| 05/27/2009 | EP2061444A2 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| 05/27/2009 | EP2061346A1 Non-allergenic ingredients and food products |
| 05/27/2009 | EP1866286B1 Pyridine derivatives useful as inhibitors of pkc-theta |
| 05/27/2009 | EP1594497B1 Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
| 05/27/2009 | EP1519915B1 Tricyclic steroid hormone nuclear receptor modulators |
| 05/27/2009 | EP1366075B1 New interferon beta-like molecules |
| 05/27/2009 | EP1351672B1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 05/27/2009 | EP1292678B1 G-protein coupled receptors |
| 05/27/2009 | EP1161562B1 Deleted sequences in m. bovis bcg/m. bovis or m. tuberculosis, method for detecting mycobacteria using said sequences and vaccines |
| 05/27/2009 | EP1156826B1 Product and method for treatment of conditions associated with receptor-desensitization |
| 05/27/2009 | EP1037651B1 Small peptides and methods for treatment of asthma and inflammation |
| 05/27/2009 | EP1003850B1 Inhibitors of dna immunostimulatory sequence activity |
| 05/27/2009 | EP0959899B1 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION |